Anti-Alpha-V Immunoliposome Composition, Methods, and Uses
    1.
    发明申请
    Anti-Alpha-V Immunoliposome Composition, Methods, and Uses 审中-公开
    抗α-V免疫脂质体组成,方法和用途

    公开(公告)号:US20090196913A1

    公开(公告)日:2009-08-06

    申请号:US12119012

    申请日:2008-05-12

    CPC分类号: A61K9/127 A61K31/704

    摘要: An immunoliposome composition targeted to the alpha-V-integrin subunit of integrin receptors comprised of ligand-targeted liposomes bearing at least one targeting-ligand derived from an antibody and having binding specificity for at least one integrin receptor comprising an alpha-V subunit including αvβ1, αvβ3 αvβ5, αvβ6, or αvβ8 integrin cell receptors is described. The antibody-derived targeting ligand may be a Fab′ fragment, a scFv, or a the like. Binding of the immunoliposome to αv-integrin expressing cells, preferably results in internalization of the immunoliposome for cytoplasmic delivery of a liposome-entrapped agent.

    摘要翻译: 靶向由整合素受体组成的α-V整联蛋白亚单位的免疫脂质体组合物,其由具有至少一种衍生自抗体的靶向配体的配体靶向脂质体组成,并且对至少一种整合素受体具有结合特异性,所述整合素受体包含α-V亚基,包括alphavbeta1 ,alphavbeta3 alphavbeta5,alphavbeta6或alphavbeta8整联蛋白细胞受体。 抗体衍生的靶向配体可以是Fab'片段,scFv等。 免疫脂质体与表达表达α-融合蛋白的细胞的结合优选地导致免疫脂质体内在化,用于脂质体包裹的药物的细胞质递送。

    LIPOSOME FORMULATIONS OF BORONIC ACID COMPOUNDS
    3.
    发明申请
    LIPOSOME FORMULATIONS OF BORONIC ACID COMPOUNDS 审中-公开
    硼酸化合物的制备方法

    公开(公告)号:US20090092662A1

    公开(公告)日:2009-04-09

    申请号:US12195795

    申请日:2008-08-21

    IPC分类号: A61K9/127 A61K31/69 A61P35/00

    摘要: A liposome composition comprised of liposomes having a peptide boronic acid proteasome inhibitor compound entrapped in the liposomes is described. More specifically, liposomes having a compound of Formula I or II entrapped in the interior aqueous compartment are loaded with a peptide boronic acid compound, to form a boronate ester compound inside the liposomal aqueous compartment. In one embodiment, the liposomes have an outer coating of hydrophilic polymer chains and are used to treat a solid tumor in a subject.

    摘要翻译: 描述了包含脂质体中包含肽硼酸蛋白酶体抑制剂化合物的脂质体的脂质体组合物。 更具体地说,将含有式I或II化合物的脂质体包埋在内部水性室中,装载有肽硼酸化合物,以在脂质体水性隔室内形成硼酸酯化合物。 在一个实施方案中,脂质体具有亲水性聚合物链的外涂层,并且用于治疗受试者中的实体瘤。

    Method of pulmonary administration of an agent
    4.
    发明申请
    Method of pulmonary administration of an agent 审中-公开
    药物的肺部给药方法

    公开(公告)号:US20050025822A1

    公开(公告)日:2005-02-03

    申请号:US10856559

    申请日:2004-05-27

    IPC分类号: A61K9/00 A61K9/127 C12N15/88

    摘要: A method for administering a therapeutic or diagnostic agent to a subject is described. The method includes providing a suspension of liposomes comprised of one or more of vesicle-forming lipids selected from (i) a vesicle-forming lipid derivatized with a hydrophilic polymer and (ii) a neutral lipopolymer, said liposomes being associated with said therapeutic or diagnostic agent, forming an aerosol of said liposome suspension; and administering the aerosol to the subject by inhalation. The liposome formulation delivers intact liposomal particles to the respiratory tract of said subject to form a depot of therapeutic agent therein with no observable provocation of an immune response, as measured by neutrophil or macrophage cell count in the lung after administration.

    摘要翻译: 描述了向受试者施用治疗剂或诊断剂的方法。 该方法包括提供脂质体的悬浮液,其由一种或多种形成囊泡的脂质组成,所述脂质体选自(i)用亲水性聚合物衍生的囊泡形成脂质和(ii)中性脂质聚合物,所述脂质体与所述治疗或诊断相关联 形成所述脂质体悬浮液的气溶胶; 并通过吸入将烟雾剂施用于受试者。 脂质体制剂将完整的脂质体颗粒递送到所述受试者的呼吸道,以在其中形成治疗剂的贮库,其中不存在可观察到的免疫应答挑衅,如通过给药后肺中的嗜中性粒细胞或巨噬细胞细胞计数所测量的。